ClinicalTrials.gg
WithdrawnNCT05082571CONVERSIONUpdated Oct 1, 2025

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

A Phase 3 interventional study of vadadustat in Anemia of Chronic Kidney Disease, sponsored by Akebia Therapeutics. Withdrawn at 1 site in United States. Open to participants aged 4 Months to 16 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Akebia Therapeutics · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
4 Months to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
25th of 27
0 · median 60
Started
2025
with 1 other
Phase 3
14 of 27
none open now
Registered
24th of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 25th largest by enrollment, is one of 2 that started in 2025, is one of 14 in phase 3, and was the 24th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 4 Months to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of once daily dosing of vadadustat for the treatment of pediatric participants with anemia of Chronic Kidney Disease (CKD) after conversion from an Erythropoiesis Stimulating Agent (ESA).

03

Conditions studied

  • Anemia of Chronic Kidney Disease

Keywords

  • anemia
  • kidney disease
  • vadadustat
  • pediatric population
  • children
  • chronic kidney disease
  • erythropoiesis stimulating agent
  • dialysis
  • hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor
04

Who can participate

Ages eligible
4 Months to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of anemia of chronic kidney disease (CKD)
  • Diagnosis of non-dialysis-dependent (NDD) CKD with an estimated of greater than (>) 10 and less than (\<) 60 milliliters/minute/1.73 meters\^2 (mL/min/1.73 m\^2) or diagnosis of dialysis dependent (DD) CKD
  • Mean (Hb) between 9.0 and 12.0 grams/deciliters (g/dL) (inclusive)
  • Transferrin Saturation ≥ 20%

Exclusion criteria

Exclusion Criteria:

  • Anemia due to a cause other than CKD
  • Active bleeding or recent blood loss
  • History of sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic , myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
  • Red Blood Cells transfusion within 4 weeks
  • Serum albumin level less than 2.5 g/dL
  • Uncontrolled hypertension
  • Active malignancy or treatment for malignancy within the past 2 years prior to Screening
  • Evidence of iron overload or diagnosis of hemochromatosis
  • Known to vadadustat or any in vadadustat tablet
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Vadadustat

    Cohort 1: participants with ≥12 years to \<17 years; Cohort 2: participants with ≥6 years to \<12 years; Cohort 3(a): participants with ≥2 years to \<6 years; and Cohort 3(b): participants with ≥4 months to \<2 years

    Drug: vadadustat

Interventions

  • Vadadustat tablet orally once a day for 52 weeks

    Also known as: AKB-6548

06

What researchers measure

Primary outcomes

  1. Mean Change in Hemoglobin (Hb) Values Between Baseline and the Primary Evaluation Period (Average Hb From Weeks 21 to 28)

    Time frame: Baseline; Weeks 21 to 28

Secondary outcomes

  1. Time to Achieve Hb Levels of ≥10.0 grams/deciliters (g/dL)

    Time frame: Up to Week 52

  2. Number of Participants With Mean Hb Values Within the Target Range During the Primary Evaluation Period

    Time frame: From Week 21 to Week 28

  3. Number of Participants With Mean Hb Values Within the Target Range During the Extension Period

    Time frame: From Week 29 to Week 52

  4. Number of Participants With Treatment-emergent Adverse Events and who Discontinued From the Study due to Adverse Events

    Time frame: Up to Week 56

  5. Maximum Observed Plasma Concentration (Cmax) of Vadadustat and its Metabolites

    Time frame: Pre-dose and post-dose at intermediate time points up to 28 weeks

  6. Time to Reach Cmax (Tmax) of Vadadustat and its Metabolites

    Time frame: Pre-dose and post-dose at intermediate time points up to 28 weeks

  7. Area Under the Plasma Concentration-Time Curve From 0 to Last Quantifiable Concentration (AUC 0-t) of Vadadustat and its Metabolites

    Time frame: Pre-dose and post-dose at intermediate time points up to 28 weeks

  8. Terminal Elimination Half-Life (t1/2) of Vadadustat and its Metabolites

    Time frame: Pre-dose and post-dose at intermediate time points up to 28 weeks

  9. Change From Baseline in Serum Erythropoietin (EPO)

    Time frame: Pre-dose and post-dose at intermediate time points up to 28 weeks

  10. Change From Baseline in Reticulocyte Count

    Time frame: Pre-dose and post-dose at intermediate time points up to 28 weeks

  11. Change From Baseline in Hb levels

    Time frame: Pre-dose and post-dose at intermediate time points up to 28 weeks

07

Study locations

1 site
  • Research Site
    Hackensack, New Jersey 07601, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Jul 2026, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2021
First posted
Oct 19, 2021
StartEst.
Jan 2025
Primary completionEst.
Jul 2026
CompletionEst.
Oct 2026
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05082571
Responsible party
Sponsor
First posted
Oct 19, 2021
Start date
Jan 2025 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Oct 1, 2025

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion